HER2-Positive Gastric Cancer

HER2-Positive Gastric Cancer


The HER2-Positive Gastric Cancer market is a dynamic and rapidly evolving sector within the oncology landscape, characterized by groundbreaking advancements and innovative treatments. This specialized market focuses on addressing the specific challenges posed by gastric cancers that overexpress the human epidermal growth factor receptor 2 (HER2) protein. These advancements hold significant promise for improving patient outcomes, transforming the diagnosis, treatment, and prognosis of HER2-positive gastric cancer.

The HER2-Positive Gastric Cancer Market is expected to grow at a strong CAGR of ~7% during the forecast period. The driving factors for the HER2-positive gastric cancer market include the rising incidence and prevalence of gastric cancer worldwide, as well as advances in targeted therapy. For example, the rising incidence and prevalence of gastric cancer is driving the market for HER2-positive gastric cancer treatments. According to the World Health Organization, gastric cancer is the fifth most common cancer worldwide, and the incidence and prevalence are increasing in many parts of the world. This trend is likely to drive the demand for effective treatments for HER2-positive gastric cancer. The integration of precision medicine, molecular profiling, and genetic insights is ushering in a new era of tailored treatment strategies that optimize efficacy while minimizing side effects. Telemedicine and remote care technologies are increasingly playing a vital role in the HER2-Positive Gastric Cancer market, ensuring patients have access to specialized expertise regardless of their geographic location.
  • Based on end-users, the HER2-positive gastric cancer market is segmented into hospitals, specialty cancer centers, and others. Hospitals are often at the forefront of cancer treatment, providing a wide range of medical services and expertise. They have the advantage of offering comprehensive care, including surgery, chemotherapy, targeted therapy, and supportive care, all under one roof. Hospitals are the leading segment due to their accessibility, familiarity to patients, and the ability to provide a holistic approach to cancer management.
  • For a better understanding of the market adoption of the HER2-Positive Gastric Cancer industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and Rest of World. North America dominated the HER2-Positive Gastric Cancer market in 2022. North America is expected to lead the HER2-positive gastric cancer market due to several factors, including the high prevalence of gastric cancer, the availability of advanced healthcare infrastructure, and the high healthcare expenditure in the region. For instance, according to the American Cancer Society, gastric cancer is the fifth most common cancer in the United States, with over 27,000 new cases diagnosed each year. Additionally, the availability of advanced healthcare infrastructure and the high healthcare expenditure in the region provide a favorable environment for the development and commercialization of HER2-positive gastric cancer treatments. Moreover, the presence of several leading biopharmaceutical companies with a strong pipeline of HER2-targeted therapies is responsible for the growth of the market in the region. For instance, Roche, which markets trastuzumab, and Pfizer, which markets lapatinib, have a strong presence in the region and are expected to continue to invest in the development of HER2-targeted therapies for gastric cancer.
  • Some of the major players operating in the market include Roche, Eli Lilly and Company, Merck & Co., Bristol Myers Squibb, Pfizer, Novartis, Daiichi Sankyo, MacroGenics, Taiho Pharmaceutical, and Five Prime Therapeutics.


1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the HER2-Positive Gastric Cancer Market
2.2. Research Methodology of the HER2-Positive Gastric Cancer Market
2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 HER2-POSITIVE GASTRIC CANCER MARKET REVENUE (USD Mn), 2023F-2030F
6 MARKET INSIGHTS BY TREATMENT TYPE
6.1. Chemotherapy
6.2. Targeted Therapy
6.3. Immunotherapy
6.4. Combination Therapies
7 MARKET INSIGHTS BY END-USERS
7.1. Hospitals
7.2. Specialty Cancer Centers
7.3. Others
8 MARKET INSIGHTS BY REGION
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Rest of North America
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. U.K.
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. Rest of APAC
8.4. Rest of the World
9 HER2-POSITIVE GASTRIC CANCER MARKET DYNAMICS
9.1. Market Drivers
9.2. Market Challenges
9.3. Impact Analysis
10 HER2-POSITIVE GASTRIC CANCER MARKET OPPORTUNITIES
11 HER2-POSITIVE GASTRIC CANCER MARKET TRENDS
12 PRICING ANALYSIS
13 COMPETITIVE SCENARIO
13.1. Competitive Landscape
13.1.1. Porters Fiver Forces Analysis
14 COMPANY PROFILED
14.1. Roche
14.2. Eli Lilly and Company
14.3. Merck & Co.
14.4. Bristol Myers Squibb
14.5. Pfizer
14.6. Novartis
14.7. Daiichi Sankyo
14.8. MacroGenics
14.9. Taiho Pharmaceutical
14.10. Five Prime Therapeutics
15 DISCLAIMER

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings